FKBP1A sirna

FKBP1A siRNA (Human)

Cat. Num. AAA8224971

• Gene Names: FKBP1A; FKBP1; PKC12; PKCI2; FKBP12; PPIASE; FKBP-12; FKBP-1A
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: FKBP1A; FKBP1A siRNA (Human); FKBP1; FKBP12; Peptidyl-prolyl cis-trans isomerase FKBP1A; PPIase FKBP1A; 12 kDa FK506-binding protein; 12 kDa FKBP; FKBP-12; Calstabin-1; FK506-binding protein 1A; FKBP-1A; Immunophilin FKBP12; Rotamase; FKBP1A sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: FKBP1A siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 108

• Applicable Applications for FKBP1A sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FKBP1A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for FKBP1A sirna

siRNA to inhibit FKBP1A expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4503725
• NCBI GeneID: 2280
• NCBI Accession #: NP_000792.1
• NCBI GenBank Nucleotide #: NM_000801.4
• UniProt Accession #: P62942; P20071; Q4VC47; Q6FGD9; Q6LEU3; Q9H103; Q9H566; D3DVW6
• Molecular Weight: 11,951 Da
• NCBI Official Full Name: peptidyl-prolyl cis-trans isomerase FKBP1A isoform a
• NCBI Official Synonym Full Names: FK506 binding protein 1A, 12kDa
• NCBI Official Symbol: FKBP1A
• NCBI Official Synonym Symbols: FKBP1; PKC12; PKCI2; FKBP12; PPIASE; FKBP-12; FKBP-1A
• NCBI Protein Information: peptidyl-prolyl cis-trans isomerase FKBP1A
• UniProt Protein Name: Peptidyl-prolyl cis-trans isomerase FKBP1A
• Protein Family: Peptidyl-prolyl cis-trans isomerase
• UniProt Gene Name: FKBP1A
• UniProt Synonym Gene Names: FKBP1; FKBP12; PPIase FKBP1A; 12 kDa FKBP; FKBP-12; FKBP-1A
• UniProt Entry Name: FKB1A_HUMAN

NCBI Description

The protein encoded by this gene is a member of the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. The protein is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin. It interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. It also interacts with multiple intracellular calcium release channels, and coordinates multi-protein complex formation of the tetrameric skeletal muscle ryanodine receptor. In mouse, deletion of this homologous gene causes congenital heart disorder known as noncompaction of left ventricular myocardium. Multiple alternatively spliced variants, encoding the same protein, have been identified. The human genome contains five pseudogenes related to this gene, at least one of which is transcribed. [provided by RefSeq, Sep 2008]

Uniprot Description

FKBP12: an immunophilin and peptidyl-prolyl cis-trans isomerase that binds to the immunosuppressant drugs FK506 (a.k.a. tacrolimus or Fujimycin) and rapamycin (a.k.a. Sirolimus). The FKBP12/rapamycin complex binds NFAT transcription factors and inhibits the induction of T cell genes including IL-2, IL-3, IL-4, TNF-alpha and GM-CSF. FK506 is used in treating patients after organ transplant and those suffering from autoimmune disorders. The immunosuppressant activity of FKBP12 is not apparently related to its prolyl isomerase activity. The FKBP12/rapamycin complex inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex1 (mTORC1). mTORC1 contains Raptor, mLST8, and PRAS40, and interacts with DEPTOR, which inhibits its activity. mTOR, a S/T protein kinase, is a central regulator of cellular growth and metabolism. Its inhibition enhances the dependence on aerobic glycolysis in leukemic cells.

Protein type: EC 5.2.1.8; Isomerase

Chromosomal Location of Human Ortholog: 20p13

Cellular Component: endoplasmic reticulum membrane; sarcoplasmic reticulum membrane; membrane; cytoplasm; nerve terminal; cytosol; Z disc

Molecular Function: protein binding; signal transducer activity; protein homodimerization activity; enzyme binding; FK506 binding; peptidyl-prolyl cis-trans isomerase activity; macrolide binding; activin binding; Hsp70 protein binding; calcium channel inhibitor activity; SMAD binding; transforming growth factor beta receptor binding

Biological Process: heart morphogenesis; protein maturation via protein folding; protein peptidyl-prolyl isomerization; positive regulation of protein binding; protein folding; T cell activation; response to caffeine; T cell proliferation; regulation of protein localization; muscle contraction; negative regulation of protein amino acid phosphorylation; transforming growth factor beta receptor signaling pathway; negative regulation of release of sequestered calcium ion into cytosol; fibril organization and biogenesis; ventricular cardiac muscle morphogenesis; protein refolding; response to iron ion; regulation of immune response; positive regulation of I-kappaB kinase/NF-kappaB cascade; cytokine and chemokine mediated signaling pathway; regulation of activin receptor signaling pathway; SMAD protein complex assembly; negative regulation of protein phosphatase type 2B activity; 'de novo' protein folding; positive regulation of protein ubiquitination; release of sequestered calcium ion into cytosol